Company Announcement no. 2/2012



To: NASDAQ OMX Copenhagen A/S
Hørsholm, Denmark, January 25, 2012



Veloxis Pharmaceuticals Announces Financial Calendar for 2012


Veloxis Pharmaceuticals A/S (OMX: VELO) today announced financial calendar for
2012.


7. March, 2012: Release of Annual Report 2011.

18 April, 2012: Annual General Meeting.

15 May, 2012: Interim Report for the 1st Quarter
‐ for the period 1 January to 31 March, 2012.

22 August, 2012: Interim Report for the 2nd Quarter –
for the period 1 January to 30 June, 2012.

14 November, 2012: Interim Report for the 3rd Quarter – for
the period 1 January to 30 September, 2012.



For more information, please contact:


Veloxis Pharmaceuticals A/S


Johnny Stilou
William J. Polvino

CFO
President & CEO

Phone: (+45) 21 227 227
Phone: (+1) 732 321 3202

Email: [email protected]
Email: [email protected]



About Veloxis Pharmaceuticals


Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis
Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company.
Clinical development is the core of Veloxis’ efforts to develop a product
portfolio which includes the Company’s lead product candidate, LCP‐Tacro™, for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. Veloxis adapts new technologies on a fast
commercial timetable. Veloxis’ unique, patented delivery technology, MeltDose®,
can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only
for a broad spectrum of drugs already on the market but also for new chemical
entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the
U.S. market and a diversified near and medium term pipeline with three clinical
stage product candidates and a number of projects in preclinical development.
Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX:
VELO.


For further information, please visit www.veloxis.com.

250112 Veloxis Announces Financial Calendar 2012.pdf